Reshma Ramachandran, MD, MPP, MHS, not only believes in equitable access to healthcare and medical products but is a formidable force in advocating for it.
Reshma Ramachandran, MD, MPP, MHS
Assistant Professor of Medicine (General Medicine)Cards
About
Reshma Ramachandran is a primary care physician trained in family medicine and health services researcher. Her research focuses on developing evidence-driven strategies to ensure equitable access to meaningfully effective and safe health innovations in the United States and abroad.
Research
Publications
2024
HPR82 Assessment of Supporting Evidence and Postmarketing Requirements for Therapeutic Indications With Real-Time Oncology Drug Review, 2018-2023
Mooghali M, Mohammad A, Wallach J, Mitchell A, Ross J, Ramachandran R. HPR82 Assessment of Supporting Evidence and Postmarketing Requirements for Therapeutic Indications With Real-Time Oncology Drug Review, 2018-2023. Value In Health 2024, 27: s208. DOI: 10.1016/j.jval.2024.03.1151.Peer-Reviewed Original ResearchHPR109 Evaluation of Evidence Informing Medicare’s Coverage With Evidence Development Decision Updates
Mooghali M, Moneer O, Janda G, Dhruva S, Ross J, Ramachandran R. HPR109 Evaluation of Evidence Informing Medicare’s Coverage With Evidence Development Decision Updates. Value In Health 2024, 27: s214. DOI: 10.1016/j.jval.2024.03.1178.Peer-Reviewed Original ResearchAssociations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments
Wallach J, Yoon S, Doernberg H, Glick L, Ciani O, Taylor R, Mooghali M, Ramachandran R, Ross J. Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments. JAMA 2024, 331: 1646-1654. PMID: 38648042, PMCID: PMC11036312, DOI: 10.1001/jama.2024.4175.Peer-Reviewed Original ResearchConceptsMeta-analysesChronic diseasesFood and Drug AdministrationMeta-regression analysisMeta-analyses of observational studiesSurrogate markerClinical outcomesClinical trialsMeta-analysisEvidence of associationPublished meta-analysesStrength of associationMeta-analyses of clinical trialsChronic disease treatmentFood and Drug Administration tableResults of meta-regression analysisOutcome pairsFood and Drug Administration approvalMain OutcomesData extractionSystematic reviewStatistically significant resultsObservational studyPooled analysisDrug AdministrationFunding of evidence included within public comments submitted to inform Medicare national coverage determinations
Lu A, Ji R, Magee M, Ross J, Ramachandran R, Redberg R, Dhruva S. Funding of evidence included within public comments submitted to inform Medicare national coverage determinations. Health Affairs Scholar 2024, 2: qxae064. PMID: 38919964, PMCID: PMC11196998, DOI: 10.1093/haschl/qxae064.Peer-Reviewed Original ResearchCenters for Medicare & Medicaid ServicesScientific journal articlesNational Coverage DeterminationPublic commentsCoverage determinationCross-sectional studyMedicare national coverage determinationsJournal articlesMedicare coverage decisionsCoverage of itemsMedicaid ServicesMedicare beneficiariesCommentsMedicare coverageGreater fundingMedicareAuthor disclosuresArticleCoverage decisionsEvaluation of benefitsFunding statementsSupport researchImplications for Public Health Regulation if Chevron Deference Is Overturned
Agrawal S, Ross J, Ramachandran R. Implications for Public Health Regulation if Chevron Deference Is Overturned. JAMA 2024, 331: 1443-1444. PMID: 38506706, DOI: 10.1001/jama.2024.3654.Peer-Reviewed Original ResearchPremarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals
Mooghali M, Mohammad A, Wallach J, Mitchell A, Ross J, Ramachandran R. Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals. JAMA Network Open 2024, 7: e249233. PMID: 38691363, PMCID: PMC11063797, DOI: 10.1001/jamanetworkopen.2024.9233.Peer-Reviewed Original ResearchCharacterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study
Mooghali M, Mitchell A, Skydel J, Ross J, Wallach J, Ramachandran R. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study. BMJ Medicine 2024, 3: e000802. PMID: 38596814, PMCID: PMC11002412, DOI: 10.1136/bmjmed-2023-000802.Peer-Reviewed Original ResearchNational Comprehensive Cancer NetworkNational Comprehensive Cancer Network guidelinesComprehensive Cancer NetworkFood and Drug AdministrationCancer NetworkUS Food and Drug AdministrationCategories of evidenceAccelerated approvalCross sectional studyDrug treatmentConfirmatory trialsClinical benefitTrial resultsOncological indicationsTraditional approvalGuideline recommendationsOutcome measuresSectional studyApproval statusFDA decisionRecommended alignmentOncologyUpdate recommendationsPostapproval trialsGuidelinesLessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications.
Nagel K, Ramachandran R, Lipska K. Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications. Diabetes Care 2024, 47: 1246-1256. PMID: 38536964, PMCID: PMC11272967, DOI: 10.2337/dci23-0042.Peer-Reviewed Original ResearchOut-of-pocket paymentsInflation ratePrice hikesPolicy prescriptionsPriceReduced priceHealth insuranceMarket entryPolicy evaluationDrug pricesGovernment negotiatorsBiosimilar competitionPharmacy benefit managersAnticompetitive practicesInflationFederal interventionIncreased enforcementPolicyInsulin pricesPublication productivityReduction ActFederal levelDrug manufacturersBenefit managersCompetitionMedicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016–2019 data
Qureshi O, Ramachandran R, Ross J. Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016–2019 data. Journal Of Pharmaceutical Policy And Practice 2024, 17: 2312374. PMID: 38434725, PMCID: PMC10906125, DOI: 10.1080/20523211.2024.2312374.Peer-Reviewed Original ResearchDrug spendingPrice negotiationsPrescription drug expendituresAnnual drug spendingInflation Reduction ActMedicare pricesSpending dataReduction ActMedicare spendingDrug expendituresSpendingDrug pricesCenters for Medicare & Medicaid ServicesMedicare Part BInflationPriceAnnual Medicare spendingEligibility requirementsMedicareNegotiationExpenditureUS FDA breakthrough therapy designation and consumer drug advertising: a recipe for confusion
Patel N, Mohammad A, Ross J, Ramachandran R. US FDA breakthrough therapy designation and consumer drug advertising: a recipe for confusion. The BMJ 2024, 384: e076138. PMID: 38383007, DOI: 10.1136/bmj-2023-076138.Peer-Reviewed Original Research
Links & Media
News
- July 06, 2024Source: MSN
Chevron doctrine ruling a 'gut-punch' for US health and environment – experts
- June 26, 2024
Yale CRRIT Researchers Examine Cancer Drug Guidelines and FDA Approvals
- June 13, 2024Source: Nature
Unease as US drug agency weighs its use of independent scientists
- June 12, 2024Source: ABC News
SCOTUS ruling on mifepristone could have lasting impact on FDA regulation: Experts